Advantage lands NIA funding to advance repurposed Alzheimer’s drug

Company targets confirmatory trials of immunomodulator shown to slow cognitive decline when used as a control arm. Longevity biotech Advantage Therapeutics has secured a $2.5 million Phase II Small Business Innovation Research grant from the National Institute on Aging to advance its Alzheimer’s dis…